Use of amantadine in Parkinson's disease: Results of a double blind trial.

Category Primary study
JournalBritish medical journal
Year 1970

This article is included in 1 Systematic review Systematic reviews (1 reference)

This article is part of the following matrixes of evidence:
Loading references information
In a four-week double-blind trial of 62 patients with Parkinsonism 29 were treated withamantadine and 33 with a placebo. Modest but statistically significant improvement was observed in the first group, optimum benefit occurring after the first two weeks. Patients' reactions to the drug were favourable in 79%, and side effects were insignificant. Though amantadine appears to be a useful additive drug in the treatment of Parkinsonism, its value as a single treatment is as yet undetermined.
Epistemonikos ID: 98f98570f0f1852f704e39e89415c44b165b39fa
First added on: Dec 12, 2017